Pharmacotherapy for Alzheimer's disease and other dementias

Current Opinion in Psychiatry

Volumn 15, Issue 4, 2002, Pages 403-409

  Herrmann, Nathan ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; Pharmacotherapy

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; CARBAMAZEPINE; CEREBROLYSIN; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DONEPEZIL; ESTROGEN; FLUOXETINE; GALANTAMINE; HYDROXYCHLOROQUINE; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; RIVASTIGMINE; SEROTONIN AGONIST; SERTRALINE; SEX HORMONE; TESTOSTERONE ENANTATE; VALPROATE SEMISODIUM; VALPROIC ACID;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BEHAVIOR; CLINICAL TRIAL; COGNITION; COST EFFECTIVENESS ANALYSIS; DEGENERATIVE DISEASE; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; HORMONAL THERAPY; HUMAN; LEWY BODY; LONG TERM CARE; PROPHYLAXIS; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0036303097     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200207000-00010     Document Type: Review

References (46)

1. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type
2. Diagnosis and treatment of Alzheimer disease and related disorders
3. The recognition, assessment and management of dementing disorders: Conclusions from the Canadian Consensus Conference on Dementia
4. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
5. Tracking cognitive decline in Alzheimer's Disease using the Mini-Mental State Examination: A meta-analysis
6. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
7. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
8. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
9. Galantamine: A randomized double-blind, dose comparison in patients with Alzheimer's disease
10. Effects of a flexible galantamine dose in Alzheimer's disease: A randomized, controlled trial
11. Assessment of health economics in Alzheimer's disease (AHEAD): Galantamine treatment in Canada
12. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
13. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
14. Cholinergic markers in elderly patients with early signs of Alzheimer disease
15. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression
16. APOE genotype: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease
17. Effects of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET
18. Amyloid precursor protein in platelets of patients with Alzheimer disease
19. Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial
20. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised double blind placebo controlled international study
21. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
22. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial
23. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: A randomized controlled trial
24. Cognitive function in postmenopausal women treated with raloxifene
25. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease
26. High-dose estradiol improves cognition for women with AD: Results of a randomized study
27. Testoterone supplementation improves spatial and verbal memory in healthy older men
28. Clinical trial of indomethicin in Alzheimer's disease
29. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
30. A randomized controlled trial of prednisone in Alzheimer's disease: Alzheimer's Disease Cooperative Study
31. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease
32. Effect of hydroxchloroquine on progression of dementia in early Alzheimer's disease: An 18-month randomised, double-blind, placebo-controlled study
33. A 28 week, double-blind, placebo-controlled study with cerebrolysin in patients with mild to moderate Alzheimer's disease
34. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease
35. Recommendations for the management of the behavioral and psychological symptoms of dementia
36. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease
37. Dementia with Lewy bodies treated with rivastigmine: Effects on cognition, neuropsychiatric symptoms, and sleep
38. The role of serotonin in the behavioral and psychological symptoms of dementia
39. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease
40. Double-blind trial of imipramine in Alzheimer's disease in patients with and without depression
41. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the Depression in Alzheimer's Disease Study
42. Fluvoxamine for psychosis in Alzheimer's disease
43. The expert consensus guideline series: Treatment of agitation in older persons with dementia
44. Placebo-controlled study of divalproex sodium for agitation in dementia
45. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial
46. Occurrence of thrombocytopenia in psychiatric patients taking valproate